Now the Advisory Council on the Misuse of Drugs (ACMD) will review the classification and is likely to recommend the drug be downgraded to class B. The body will hold a special evidence session next Friday during which it will hear the latest data on the drugs' effects on the brain and its toxicity. Its decision will be announced next year.